Bristol Myers Squibb invests in Dragonfly Therapeutics, a company co-founded by IVRI faculty director, David Raulet
IVRI faculty director, David Raulet, comments in this week Science edition, a publication by Zhou et al. showing that, cytotoxic lymphocytes both kill target cells and activate additional inflammatory signals through pyroptosis.
Dan Fletcher’s lab reveals how a viral pathogen hijacks branched actin network assembly to drive cell-cell fusion; a mechanism essential for tissue development and used by some viruses to form pathological syncytia.
IVRI is proud to feature “Fab” article from UC Berkeley Pr. Jay Groves. Understanding how T Cell receptors (TCRs) are activated is fundamental in the cancer immunotherapy field. The present study is probably the first to put a quantitative measure on specific potency of a synthetic TCR ligand, and identifies the specific H57-Fab’ epitope as a potent target; both of these insights being essential in drug development.
IVRI faculty Prof. Greg Barton recently demonstrated the importance of the location of Toll-like-receptors (TLRs). In a new study published in PNAS, Alison Stanbery, Zachary Newman, and Prof. Gregory Barton show that not only location of TLR-9 is primordial, but dysregulated activation of TLR-9 at different stages of life, induced specific inflammatory response. This work helps us understand unique aspects of TLR9-driven inflammatory disease, and has relevance for studying and developing new therapeutic avenues for both infectious and autoimmune diseases.
IVRI faculty director Professor Raulet publishes on how Natural Killer cells could be used to combat cancer
IVRI Congratulates faculty Gregory Barton and Nevan Krogan on their two landmark Nature papers. This work helps us understand how finely regulated interactions between proteins and their location enables the immune system to focus specifically on pathogens.